1. aNobbs, M. S.; Rodgers, S. J.Preparation of (R)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethylpyrimidine as a drug. World Patent WO 9709317 A2, 1997.
2. bMiller, A. A.; Nobbs, M. S.; Hyde, R. M.; Leach, M. J.Preparation and formulation of phenylpyrimidines for treating central nervous system disorders. European Patent EP 372934, 1996.
3. cAlvaro, G.; Large, C.Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine or R-(−)-2,4-diamino-5-(2,3-dichlorophenyl)-6-(fluoromethyl)pyrimidine and an NK1 antagonist. World Patent WO 2008090117 A1, 2008.
4. The UK HSE has assigned a SLOD DTL (Specified Likelihood of Death Dangerous Toxic Load) for ethyl fluoroacetate as 1840 ppm·min. For example, it is estimated that, for exposure of a population to 80 ppm of ethyl fluoroacetate for 23 min (1840 ppm·min), 50% of this population would be killed [Assessment of the Dangerous Toxic Load (DTL) for Specified Level of Toxicity (SLOT) and Significant Likelihood of Death (SLOD)].http://www.hse.gov.uk/chemicals/haztox.html(accessed April 19, 2013) .
5. The first synthesis and cytostatic activity of novel 6-(fluoromethyl)purine bases and nucleosides